Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
180 hedge funds and large institutions have $2.55B invested in Intra-Cellular Therapies Inc. in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 77 increasing their positions, 49 reducing their positions, and 26 closing their positions.
304% more call options, than puts
Call options by funds: $31M | Put options by funds: $7.67M
57% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 49
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 187 → 180 (-7)
6% less capital invested
Capital invested by funds: $2.72B → $2.55B (-$173M)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$56.2M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$19.7M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$13.5M |
| 4 |
GPSPJS
General Pension Society PZU Joint Stock
Warsaw,
Poland
|
+$9.29M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$8.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$16.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13.4M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$11.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.4M |
ITCI Hedge Fund Activity: Q3 2021 in Review
180 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2021, worth a combined $2.55B — down 6.4% from $2.72B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ITCI and 19 opened new positions — a net loss of 7 holders — while 49 trimmed existing stakes and 77 added.
The largest buyer was Wasatch Advisors, adding an estimated $56.2M. The largest seller was Fidelity Investments, cutting an estimated $36.2M.
- 180 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2021, down from 187 in Q2 2021.
- Funds reported $2.55B of Intra-Cellular Therapies Inc. stock for Q3 2021, down 6.4% quarter-over-quarter.
- 19 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2021 and 26 closed out, a net change of -7 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2021 was Wasatch Advisors, an estimated $56.2M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2021 was Fidelity Investments, an estimated $36.2M sold.
Based on aggregated 13F filings for Q3 2021.